AstraZeneca buys a 12% stake in Summit for $2 billion at $18.36 a share; Summit jumps 17% after hours
The price is billed as a 10% premium to Summit's five-day average, but Summit closed Monday at $15.48, so AstraZeneca is paying about 19% over the last close. Even after the jump, the stock sits below AstraZeneca's price.
AstraZeneca agreed on Monday to invest $2 billion in newly issued Summit Therapeutics equity and to run joint trials combining Summit's lung-cancer antibody ivonescimab with one of AstraZeneca's antibody-drug conjugates, AstraZeneca said. It is buying about 108,955 convertible preferred shares, each convertible into 1,000 common shares, at a price equal to $18.36 per common share. That gives it about 12.0% of Summit's common stock, or about 10.6% fully diluted.
Summit shares rose 16.9% to $18.10 in after-hours trading, after closing the regular session at $15.48, according to Nasdaq data.
The premium is bigger than "10%"
Both companies describe the $18.36 price as the volume-weighted average of the prior five trading days plus 10%. That average reflects a stock that was sliding: Summit closed at $16.90 a week ago and at $15.48 on Monday, per Nasdaq's price history. Measured against Monday's close, AstraZeneca is paying about 18.6% more.
The other detail in the after-hours tape: at $18.10, Summit's shares are still about 1.4% below the price AstraZeneca agreed to pay. Traders did not bid the stock through the strategic buyer's price, and the stock remains well under its 52-week high of $29.23.
For AstraZeneca the cheque is small. Its market value was about $258 billion at Monday's close, so $2 billion is under 1% of it. Summit was valued at about $12.3 billion at the close.
What AstraZeneca actually gets
This is a stake plus a trial partnership, not a licensing deal. The collaboration will test ivonescimab, a PD-1/VEGF bispecific antibody, with sonesitatug vedotin (Sone-Ve), AstraZeneca's CLDN18.2-targeting antibody-drug conjugate, starting in gastrointestinal cancers. The companies say those trials will begin imminently, the two will share trial costs, and each keeps full rights to its own drug.
Beyond that, the companies signed a memorandum of understanding that says they intend to reach an agreement to combine ivonescimab with more AstraZeneca cancer medicines, including other conjugates. An MOU is an intention, not a contract, and no terms were given.
Ivonescimab was developed by China's Akeso, which sells it in China; Summit holds rights outside China. The investment is expected to close within about a week, and conversion into common stock is subject to regulatory clearances.
What traders are watching
The next hard date is November 14, 2026: Summit's release says that is the FDA's target decision date on its application for ivonescimab in EGFR-mutated non-squamous non-small cell lung cancer after progression on a targeted therapy. The application was submitted in January. Summit says ivonescimab is in 16 Phase III trials, five of them Summit-sponsored global studies, including head-to-head trials against Merck's Keytruda (pembrolizumab) in first-line lung cancer.
Related: Merck's $400 million upfront SciBrunch deal, also announced Monday, and more stock news.
Sources: AstraZeneca, Summit Therapeutics release (Business Wire), Nasdaq market data. Premium and share-price comparisons are Chronicle calculations. This is market information, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.